Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

2(40.0%)

Phase 2

1(20.0%)

Phase 1

1(20.0%)

N/A

1(20.0%)

5Total

Phase 4(2)

Phase 2(1)

Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02349841Phase 2Completed

Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis

Role: collaborator

NCT01755377Completed

New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease

Role: lead

NCT01771848Phase 1Completed

Optimization of Controlled Human Malarial Infection by Injection of P. Falciparum Sporozoites in Non-Immune Adults

Role: collaborator

NCT01755403Phase 4Completed

Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease

Role: lead

NCT01841203Completed

Dual Point-of-care Test for the Diagnosis of Yaws

Role: collaborator

NCT02143934Phase 4Completed

Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity

Role: collaborator

NCT00811421Not ApplicableCompleted

Evaluation of Alternative Antimalarial Drugs for Malaria in Pregnancy

Role: collaborator

All 7 trials loaded